Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

March 24, 2014

Primary Completion Date

June 29, 2015

Study Completion Date

June 29, 2015

Conditions
Infections, Bacterial
Interventions
DRUG

GSK2140944 Lyophile

GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.

DRUG

GSK2140944 Capsules

GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.

Trial Locations (30)

11215

GSK Investigational Site, Brooklyn

12208

GSK Investigational Site, Albany

15212

GSK Investigational Site, Pittsburgh

30909

GSK Investigational Site, Augusta

30912

GSK Investigational Site, Augusta

33027

GSK Investigational Site, Miramar

33401

GSK Investigational Site, West Palm Beach

39426

GSK Investigational Site, Carriere

41701

GSK Investigational Site, Hazard

43608

GSK Investigational Site, Toledo

45801

GSK Investigational Site, Lima

51503

GSK Investigational Site, Council Bluffs

55422

GSK Investigational Site, Minneapolis

59701

GSK Investigational Site, Butte

68510

GSK Investigational Site, Lincoln

70791

GSK Investigational Site, Zachary

77024

GSK Investigational Site, Houston

77030

GSK Investigational Site, Houston

77530

GSK Investigational Site, Channelview

85021

GSK Investigational Site, Phoenix

90502

GSK Investigational Site, Torrance

91342

GSK Investigational Site, Sylmar

91942

GSK Investigational Site, Chula Vista

GSK Investigational Site, La Mesa

92056

GSK Investigational Site, Oceanside

92120

GSK Investigational Site, Las Vegas

92804

GSK Investigational Site, Anaheim

39216-4505

GSK Investigational Site, Jackson

07109

GSK Investigational Site, Belleville

07753

GSK Investigational Site, Neptune City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02045797 - Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections | Biotech Hunter | Biotech Hunter